| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5622985 | BRISTOL MYERS SQUIBB | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
Apr, 2014
(10 years ago) | |
|
US5622985 (Pediatric) | BRISTOL MYERS SQUIBB | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
Oct, 2014
(9 years ago) | |
Pravachol is owned by Bristol Myers Squibb.
Pravachol contains Pravastatin Sodium.
Pravachol has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Pravachol are:
- US5622985
- US5622985*PED
Pravachol was authorised for market use on 31 October, 1991.
Pravachol is available in tablet;oral dosage forms.
Pravachol can be used as use of pravastatin sodium for secondary prevention of coronary events in men and women who have had a myocardial infarction and have normal cholesterol levels.
The generics of Pravachol are possible to be released after 22 October, 2014.
Drugs and Companies using PRAVASTATIN SODIUM ingredient
Market Authorisation Date: 31 October, 1991
Treatment: Use of pravastatin sodium for secondary prevention of coronary events in men and women who have had a myocardial infarction and have normal cholesterol levels
Dosage: TABLET;ORAL
PRAVACHOL family patents
